摘要
目的探讨非诺贝特联合替格瑞洛对冠心病合并高三酰甘油血症(HTG)患者脂代谢及凝血功能的影响。方法选取2021年6月—2022年12月新疆医科大学第五附属医院收治的冠心病合并HTG患者126例,采用随机数字表法将患者分为非诺贝特组(n=63)和常规组(n=63)。常规组患者给予阿司匹林、替格瑞洛及瑞舒伐他汀钙治疗,非诺贝特组患者在常规组患者治疗基础上将瑞舒伐他汀钙改为非诺贝特,所有患者均连续治疗6个月。比较两组患者治疗前后脂代谢指标(TG、TC、LDL-C、HDL-C)、凝血功能指标〔活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)及纤维蛋白原(FIB)〕及治疗期间不良反应发生率。结果治疗后,两组TG、TC、LDL-C分别低于本组治疗前,HDL-C分别高于本组治疗前(P<0.05)。治疗后,非诺贝特组TG、TC、LDL-C低于常规组(P<0.05)。治疗后,两组APTT、PT分别长于本组治疗前,FIB分别低于本组治疗前(P<0.05)。治疗后,非诺贝特组APTT、PT长于常规组(P<0.05)。非诺贝特组患者不良反应总发生率低于常规组(P<0.05)。结论非诺贝特联合替格瑞洛能够纠正冠心病合并HTG患者的脂代谢紊乱及凝血功能异常,降低不良反应发生率。
Objective To explore the effect of fenofibrate combined with ticagrelor on lipid metabolism and coagulation function in patients with coronary heart disease and hypertriglyceridemia(HTG).Methods A total of 126 patients with coronary heart disease and HTG admitted to the Fifth Affiliated Hospital of Xinjiang Medical University from June 2021 and December 2022 were selected.The patients were divided into fenofibrate group(n=63)and regular group(n=63)using a random number table method.Patients in the regular group were treated with aspirin,ticagrelor,and rosuvastatin calcium,patients in the fenofibrate group were administered fenofibrate in place of rosuvastatin calcium on the basis of nimodipine group.All patients were treated continuously for 6 months.The lipid metabolism indicators(TG,TC,LDL-C,HDL-C),coagulation function indicators[activated partial thrombin time(APTT),prothrombin time(PT),and fibrinogen(FIB)]before and after treatment and reaction incidence rate during treatment were compared between the two groups.Results After treatment,the TG,TC,LDL-C in the two groups were lower than those before treatment,the HDL-C was higher than that before treatment respctively(P<0.05).After treatment,the TG,TC,LDL-C in fenofibrate group were lower than those in regular group(P<0.05).After treatment,the APTT,PT in the two groups were longer than those before treatment,the FIB was lower than that before treatment respctively(P<0.05).After treatment,the APTT,PT in fenofibrate group were longer than those in regular group(P<0.05).The total rate of reaction incidence in fenofibrate group was lower than that in regular group(P<0.05).Conclusion Fenofibrate combined with ticagrelor can correct lipid metabolism disorders and coagulation disorders in patients with coronary heart disease and HTG,and reduce the reaction incidence rate.
作者
郑丽华
巴·巴音斯勒玛
王思瑶
张颖
ZHENG Lihua;BA·Bayinsilema;WANG Siyao;ZHANG Ying(Department of Cardiovascular Medicine,the Fifth Affiliated Hospital of Xinjiang Medical University,Urumqi 830011,China;Department of Endocrinology,the Fifth Affiliated Hospital of Xinjiang Medical University,Urumqi 830011,China;Department of Hypertension,the Fifth Affiliated Hospital of Xinjiang Medical University,Urumqi 830011,China)
出处
《实用心脑肺血管病杂志》
2024年第6期98-102,共5页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
基金
新疆维吾尔自治区自然科学基金资助项目(2018D01C300)。
关键词
冠心病
高三酰甘油血症
非诺贝特
脂代谢障碍
凝血功能
Coronary disease
Hypertriglyceridemia
Fenofibrate
Lipid metabolism disorders
Coagulation function
